To the Editor: Sulfikkarali et al. have provided interesting data in their recent article [1] . Naringenin may attenuate tumor growth in a number of other systemic malignancies.
For instance, attenuation of tumor growth is seen in gliomas. It mediates this effect by attenuating cyclooxygenase-2 expression within the cancerous cells [2] . As a result lipid peroxidation is markedly inhibited. Naringenin also alters the Bcl-2/Bax ratio. PI3K activity is also decreased at the same time. Simultaneous inhibition of protein kinase B and protein kinase C accompanies the above changes [3] . Up-regulation of Cx43 is seen. NF-κB activity is also decreased markedly [4] . These changes result in marked attenuation of intra-tumoral proliferation and accentuation of apoptosis within the gliomas. The release of cytochrome C from the mitochondria is further augmented.
Naringenin also decreases tumor growth in gastrointestinal carcinomas. For instance, in gastric carcinomas it mediates this role by augmenting the redox activity in the tumor cells [5] . Naringenin also attenuates the activity as well as levels of intra-tumoral fucose, sialic acid and hexose [6] . Attenuation of these glycoproteins further mitigates tumor growth in gastric carcinomas. Similar effects are seen in hepato-cellular carcinomas. It decreases NF-κB activity within the tumor cells. Naringenin administration up-regulates Bax while down-regulating Bcl-2 [7] . Similar inhibitory effects on VEGF activity are seen. MMP-2 and MMP-9 downregulation accompanies the above changes. PCNA expression is also decreased resulting in augmented apoptosis and inhibition of proliferation.
The above examples clearly illustrate the significant antineoplastic effects of naringenin and reaffirm the need for further studies to fully evaluate these effects.
